Aliases & Classifications for Uterine Anomalies

MalaCards integrated aliases for Uterine Anomalies:

Name: Uterine Anomalies 56
Uterine Diseases 54 42 43 71
Uterine Disease 12 15
Uterine Abnormality 54

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
uterine anomalies:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:345
OMIM 56 192000
ICD9CM 34 621.9
MeSH 43 D014591
NCIt 49 C26907
SNOMED-CT 67 12337004
ICD10 32 N85.9
MedGen 41 C0266383
SNOMED-CT via HPO 68 263681008 31401003
UMLS 71 C0042131

Summaries for Uterine Anomalies

MedlinePlus : 42 The uterus, or womb, is the place where a baby grows when a woman is pregnant. The first sign of a problem with the uterus may be bleeding between periods or after sex. Causes can include hormones, thyroid problems, fibroids, polyps, cancer, infection, or pregnancy. Treatment depends on the cause. Sometimes birth control pills treat hormonal imbalances. If a thyroid problem is the cause, treating it may also stop the bleeding. If you have cancer or hyperplasia, an overgrowth of normal cells in the uterus, you may need surgery. With two other uterine problems, tissue that normally lines the uterus grows where it is not supposed to. In endometriosis, it grows outside the uterus. In adenomyosis, it grows in the uterus's outside walls. Pain medicine may help. Other treatments include hormones and surgery.

MalaCards based summary : Uterine Anomalies, also known as uterine diseases, is related to cervix disease and endometriosis, and has symptoms including pelvic pain An important gene associated with Uterine Anomalies is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Diclofenac and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include uterus, thyroid and cervix, and related phenotype is bicornuate uterus.

Disease Ontology : 12 A female reproductive system disease that is located in the uterus.

More information from OMIM: 192000

Related Diseases for Uterine Anomalies

Diseases in the Uterine Anomalies family:

Uterine Inflammatory Disease

Diseases related to Uterine Anomalies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 cervix disease 32.5 MIR9-1 MIR34C MIR34A MIR30A MIR214 MIR21
2 endometriosis 31.2 MIR34C MIR200A MIR199A1 MIR145 MIR143 MIR141
3 leiomyoma, uterine 30.8 MIR34A MIR30A MIR21 ESR1 CYP19A1
4 endometrial adenocarcinoma 30.7 MIR34A MIR200A ESR1
5 breast cancer 30.4 MIR9-1 MIR34A MIR30A MIR21 MIR200A MIR199A1
6 colorectal cancer 30.3 U2AF1 MIR9-1 MIR34C MIR34A MIR30A MIR214
7 acrorenal-mandibular syndrome 11.1
8 pyometritis 11.0
9 endometrial disease 11.0
10 female infertility of uterine origin 11.0
11 uterine inflammatory disease 11.0
12 chronic subinvolution of uterus 11.0
13 placenta disease 11.0
14 uterine inversion 11.0
15 endometriosis of ovary 10.8 MIR9-1 MIR145 MIR141 HNF1B ESR1 CYP19A1
16 ovarian cyst 10.8 MIR145 MIR141 CYP19A1
17 luminal breast carcinoma 10.8 MIR21 H2AC18 ESR1 CYP19A1
18 bone resorption disease 10.8 MIR214 MIR199A1 H2AC18 ESR1 CYP19A1
19 endocrine organ benign neoplasm 10.8 MIR21 MIR199A1 MIR196A1 MIR17 H2AC18
20 esophagus adenocarcinoma 10.8 MIR21 MIR196A1 MIR145 MIR143
21 bone remodeling disease 10.8 MIR214 MIR199A1 H2AC18 ESR1 CYP19A1
22 muscle cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR143 H2AC18
23 pre-malignant neoplasm 10.8 MIR30A MIR17 H2AC18 ESR1 CYP19A1
24 cell type benign neoplasm 10.8 MIR21 MIR200A MIR199A1 MIR196A1 MIR17 MIR143
25 ovarian disease 10.8 MIR21 MIR199A1 MIR17 MIR145 H2AC18 ESR1
26 intestinal benign neoplasm 10.8 MIR21 MIR199A1 MIR17 MIR15A MIR143 H2AC18
27 in situ carcinoma 10.8 MIR30A MIR17 MIR143 H2AC18 ESR1 CYP19A1
28 breast carcinoma in situ 10.8 MIR30A MIR17 MIR143 ESR1 CYP19A1
29 tongue disease 10.8 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
30 ovarian serous carcinoma 10.8 MIR214 MIR21 MIR200A MIR199A1 MIR145 MIR143
31 inherited metabolic disorder 10.8 MIR9-1 MIR21 MIR199A1 MIR17 H2AC18
32 gastrointestinal system benign neoplasm 10.8 MIR21 MIR199A1 MIR196A1 MIR17 MIR15A MIR143
33 bile duct adenocarcinoma 10.8 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 H2AC18
34 muscle tissue disease 10.8 U2AF1 MIR9-1 MIR199A1 MIR196A1 H2AC18
35 uterine corpus cancer 10.8 U2AF1 MIR214 H2AC18 ESR1
36 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.8 U2AF1 MIR9-1 MIR199A1 MIR196A1 MIR17 HNF1B
37 mouth disease 10.8 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
38 retinal cancer 10.8 MIR9-1 MIR214 MIR199A1 MIR196A1 MIR17 H2AC18
39 miyoshi muscular dystrophy 1 10.8 MIR34A MIR30A MIR214 MIR21
40 uveal disease 10.8 U2AF1 MIR9-1 MIR199A1 H2AC18
41 thyroid gland papillary carcinoma 10.8 MIR9-1 MIR30A MIR200A MIR199A1 MIR17
42 bone cancer 10.8 MIR9-1 MIR214 MIR21 MIR199A1 ESR1
43 autoimmune disease of musculoskeletal system 10.8 MIR34A MIR30A MIR21 MIR196A1 H2AC18
44 bone inflammation disease 10.8 MIR34A MIR30A MIR21 MIR199A1 MIR196A1 MIR17
45 retinal vascular disease 10.8 MIR30A MIR21 MIR199A1 H2AC18
46 polymyositis 10.8 MIR30A MIR214 MIR21
47 connective tissue cancer 10.8 MIR9-1 MIR214 MIR21 MIR199A1 MIR196A1 MIR17
48 chromosomal disease 10.8 U2AF1 MIR9-1 MIR196A1 MIR17 H2AC18
49 laryngeal disease 10.8 MIR34C MIR34A MIR21 MIR196A1 MIR17 MIR143
50 rectum cancer 10.8 MIR214 MIR21 MIR200A MIR196A1 MIR17 MIR145

Graphical network of the top 20 diseases related to Uterine Anomalies:



Diseases related to Uterine Anomalies

Symptoms & Phenotypes for Uterine Anomalies

Human phenotypes related to Uterine Anomalies:

31
# Description HPO Frequency HPO Source Accession
1 bicornuate uterus 31 HP:0000813

Symptoms via clinical synopsis from OMIM:

56
G U:
uterine anomalies
uterus arcuatus
uterus bicornis unicollis

Clinical features from OMIM:

192000

UMLS symptoms related to Uterine Anomalies:


pelvic pain

Drugs & Therapeutics for Uterine Anomalies

Drugs for Uterine Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
3
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
4
leucovorin Approved Phase 4 58-05-9 6006 143
5
Enoxaparin Approved Phase 4 9005-49-6 772
6
Dalteparin Approved Phase 4 9005-49-6
7
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
8
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
9
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
13
Norethindrone Approved Phase 4 68-22-4 6230
14
Buserelin Approved, Investigational Phase 4 57982-77-1
15
tannic acid Approved Phase 4 1401-55-4
16
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
18 Anti-Arrhythmia Agents Phase 4
19 Sodium Channel Blockers Phase 4
20 Diuretics, Potassium Sparing Phase 4
21 Adjuvants, Immunologic Phase 4
22 Protective Agents Phase 4
23 Viscosupplements Phase 4
24 Anesthetics, Local Phase 4
25 Anesthetics Phase 4
26 Central Nervous System Depressants Phase 4
27 Fibrinolytic Agents Phase 4
28 Anticoagulants Phase 4
29 calcium heparin Phase 4
30 Vitamins Phase 4
31 Trace Elements Phase 4
32 Micronutrients Phase 4
33 Vitamin B Complex Phase 4
34 Vitamin B9 Phase 4
35 Nutrients Phase 4
36 Antibodies Phase 4
37 Immunoglobulins Phase 4
38 Heparin, Low-Molecular-Weight Phase 4
39 Hematinics Phase 4
40 Folate Phase 4
41 Antibodies, Antiphospholipid Phase 4
42 Immunologic Factors Phase 4
43 Pharmaceutical Solutions Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4
46 Analgesics, Non-Narcotic Phase 4
47 Cyclooxygenase Inhibitors Phase 4
48 Antirheumatic Agents Phase 4
49 Analgesics Phase 4
50 Estrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 The Effect of Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief During Hysterosalpingography Among Infertile Women In A Tertiary Hospital In Kano: A Randomized Controlled Trial Unknown status NCT02918812 Phase 4 Intracervical lidocaine;Intramuscular Diclofenac
2 Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion Unknown status NCT02868437 Phase 4
3 Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
4 Randomized Double-blind Placebo Controlled Trial to Assess the Role of Intrauterine Cornual Block (ICOB) in Combination With Direct Cervical Block in Outpatient Endometrial Ablation Completed NCT01808898 Phase 4
5 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
6 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
7 How do Different Ovarian Stimulation Protocols Affect Endometrial Receptivity During a Fresh In-vitro Fertilization Attempt Not yet recruiting NCT03755973 Phase 4 CFA;rFSH
8 3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities Unknown status NCT02682433 Phase 3
9 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
10 Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy: a Multi-center, Randomized Controlled Trial Completed NCT01893086 Phase 3
11 A Randomized Comparison of Laparoendoscopic Single-site (LESS) Hysterectomies: Total Laparoscopic Hysterectomy (TLH) Versus Laparoscopically Assisted Vaginal Hysterectomy (LAVH) Completed NCT01861067 Phase 3
12 Delayed Start vs Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase. Completed NCT02333253 Phase 3 cetrotide
13 Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin Recruiting NCT02144064 Phase 3 Heparin
14 A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer Recruiting NCT03555422 Phase 3 Selinexor;Placebo
15 Misoprostol Versus Effox (Individually or in Combination) as Cervical Ripening Agent Prior to 1st Trimesteric Surgical Evacuation Unknown status NCT02738177 Phase 2 Misoprostol;Isosorbide-5-mononitrate;misoprostol and Isosorbide-5-mononitrate
16 Three Dimensional Trans-vaginal Ultrasound to Reevaluate Arcuate Uteri Diagnosed by Hystro-salpingography Completed NCT02597816 Phase 2
17 A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis Completed NCT01190475 Phase 2 BGS649;BGS649;Placebo
18 Embryo Transfer: Embryo Expulsion and Outcome Completed NCT00905788 Phase 1, Phase 2
19 A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Completed NCT01379534 Phase 2 TKI258
20 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
21 A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors Completed NCT00561795 Phase 2 pazopanib (GW786034);carboplatin;paclitaxel
22 A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3) Completed NCT02139267 Phase 2
23 Soy Estrogen Alternative Study (SEA) Completed NCT00000612 Phase 2 estrogens, conjugated
24 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Using Cisplatin, Mitomycin, and Adriamycin in Peritoneal Surface Malignancies Also Known as Hyperthermic Intraperitoneal Chemotherapy. Recruiting NCT02349958 Phase 2
25 SIRT1-1 Antagonist Therapy Before Embryo Transfer to Improve Endometrial Receptivity and Life Pregnancy Rates Not yet recruiting NCT04184323 Phase 2 EX-527 (Selisistat);Placebo
26 Comparative Controlled Trial of Treatment of Minor Unexpected Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy Screening in Women Indicated for IVF Terminated NCT00830401 Phase 2 Ofloxacinum/Doxycycline
27 Prospective Randomized Comparison of Single-port and Three-port Laparoscopic Assisted Vaginal Hysterectomy Unknown status NCT01679548
28 Incidence and Pattern of Overactive Bladder Symptoms Occurring After Hysterectomy Unknown status NCT01683890
29 Assessment of Feasibility and Benefit of the Use of Less Than 3 Millimeter Diameter's Instruments Compared to Standard Size Instruments in Laparoscopic Hysterectomy: a Randomized Single-center Comparative Study Unknown status NCT02367703
30 Prevalence of Congenital Uterine Malformations in Women With a History of Preterm Delivery or Miscarriage Unknown status NCT01487616
31 Intrauterine Saline Washing for Detection Endometrial Disease in Patients With Abnormal Uterine Bleeding Unknown status NCT02691715
32 Patient Attitudes Regarding Abdominal Versus Transvaginal Ultrasonography for Assessment of the Cervical Length in Low Risk Patients: a Randomized Trial Unknown status NCT01482039
33 Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
34 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Unknown status NCT03121560
35 Feasibility of a Randomised Controlled Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy Unknown status NCT01825915
36 A Retrospective Analysis of a Complete Enseal Laparoscopic Vaginal Assisted Hysterectomy Versus a Traditional Suture Laparoscopic Vaginal Hysterectomy Completed NCT01217866
37 Thrombophilia and Thyroid Autoimmunity in Implantation Failure and Recurrent Miscarriage Completed NCT00485446
38 Postoperative Pain After Total Laparoscopic Hysterectomy: a Comparison of Transumbilical Single-port Access and Conventional Three-port Laparoscopic Surgery Completed NCT02390804
39 Randomized Clinical Trial of Total Versus Subtotal Abdominal Hysterectomy Completed NCT01880710
40 The Clinical and Biochemical Characteristics in Women With Different Menstrual Pattern Completed NCT01604603
41 Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy Completed NCT02065453
42 Comparison of Total Laparoscopic Hysterectomy and Laparoscopic Assisted Vaginal Hysterectomy With Over Giant Uterus of Than 500g: A Randomized Controlled Trial Completed NCT03146299
43 Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor Completed NCT01773135
44 The Role of Insulin Resistance in Recurrent Miscarriage Completed NCT02705248
45 Robotic Assisted Surgery for Treatment of Gynecological Diseases: Pilot Study Completed NCT03093675
46 New Mini-resectoscope as Alternative to Traditional Hysteroscopy in the Treatment of Uterine Lesions Completed NCT01430208
47 Fast Versus Slow Tenaculum Placement for Office Procedures: A Randomized Controlled Trial Completed NCT02716636
48 The Misoprostol Vaginal Insert Compared With Oral Misoprostol for Labour Induction in Term Pregnancies: a Pair-matched Case-control Study Completed NCT02904317
49 Hysteroscopic Assessment of Fallopian Tubal Patency Completed NCT02005263
50 Proliferative Effects of Erythropoietin on Human Endometrium Completed NCT03060603 Erythropoietin

Search NIH Clinical Center for Uterine Anomalies

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CARBOXYMETHYLCELLULOSE CALCIUM

Cochrane evidence based reviews: uterine diseases

Genetic Tests for Uterine Anomalies

Anatomical Context for Uterine Anomalies

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Anomalies:

19
Uterus

MalaCards organs/tissues related to Uterine Anomalies:

40
Uterus, Thyroid, Cervix, Breast, Ovary, Bone, Placenta

Publications for Uterine Anomalies

Articles related to Uterine Anomalies:

(show top 50) (show all 732)
# Title Authors PMID Year
1
Familial bicornuate and double uterus. 56
4841581 1974
2
[On the problem of frequent familial occurrence of uterus abnormalities]. 56
5997716 1966
3
Observations on the results of pregnancies in women resident in Belfast. II. Abortions, hydatidiform moles and ectopic pregnancies. 56
13834545 1959
4
Congenital abnormalities of the uterus and pregnancy. 56
13316096 1956
5
UTERUS DIDELPHYS. 56
20320870 1938
6
Laparoscopic supracervical hysterectomy versus endometrial ablation for women with heavy menstrual bleeding (HEALTH): a parallel-group, open-label, randomised controlled trial. 42
31522846 2019
7
Sacrospinous hysteropexy versus vaginal hysterectomy with uterosacral ligament suspension in women with uterine prolapse stage 2 or higher: observational follow-up of a multicentre randomised trial. 42
31506252 2019
8
Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy With Uterosacral Ligament Suspension on Treatment Failure in Women With Uterovaginal Prolapse: A Randomized Clinical Trial. 42
31529008 2019
9
Serum vitamin D concentrations at dry-off and close-up predict increased postpartum urine ketone concentrations in dairy cattle. 61
31759612 2020
10
Adaptive immunity in the postpartum uterus: Potential use of vaccines to control metritis. 61
31983466 2020
11
Innovations in hysteroscopic surgery: expanding the meaning of "in-office". 61
31971476 2020
12
Large pelvic mass arising from the cervical stump: A case report. 61
31970181 2020
13
Uterine 'anomalies' by ESHRE/ESGE classification: are more than half of the women really sick? 61
31994244 2020
14
Endometrial carcinoma arising in one horn of a didelphys uterus. 61
32039789 2020
15
The pathogenic role of autoantibodies in recurrent pregnancy loss. 61
31633847 2020
16
Ruptured Ectopic Pregnancy in an Accessory Horn of Uterus: A Case Report. 61
31993273 2019
17
Three-Dimensional Volume Imaging in Gynecology. 61
31677753 2019
18
Quantitative Sonoelastographic Assessment of the Normal Uterus Using Shear Wave Elastography: An Initial Experience. 61
31077426 2019
19
Uterine microbiome-low biomass and high expectations†. 61
30544156 2019
20
Risk factors for placenta accreta spectrum: findings from the Japan environment and Children's study. 61
31775687 2019
21
Reproductive Implications and Management of Congenital Uterine Anomalies: Scientific Impact Paper No. 62 November 2019. 61
31749334 2019
22
Uterine anomalies and endometriosis: an overview. 61
31755672 2019
23
[Place of ultrasound in the management of Mayer-Rokitansky-Kuster-Hauser syndrome. Observational study from 2000 to 2017 within university hospital of Strasbourg]. 61
31280033 2019
24
Targeted transcript analysis revealed association of suboptimal expression of certain endometrial immunity-related genes with disparate uterine diseases in zebu cows. 61
31197726 2019
25
Is there a role for placental histopathology in predicting the recurrence of preterm birth? 61
31422460 2019
26
Cervical length and quantitative fetal fibronectin in the prediction of spontaneous preterm birth in asymptomatic women with congenital uterine anomaly. 61
31132343 2019
27
T-shaped Uterus in the 21st Century (Post DES era) - We Need to Know More! 61
32038076 2019
28
Comparison and appraisal of (inter)national recurrent pregnancy loss guidelines. 61
31182358 2019
29
Gynecological anomalies in patients with anorectal malformations. 61
31270672 2019
30
[Clinical analysis for 156 cases of vaginoscopy in young girls and adolescent girls]. 61
31645493 2019
31
A lariat-based dilatation device for hysteroscopy: an in vitro study. 61
31700898 2019
32
Transcriptome Profiling Analysis of Bovine Vaginal Epithelial Cell Response to an Isolated Lactobacillus Strain. 61
31506261 2019
33
Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study. 61
31425735 2019
34
Congenital Uterine Malformation by Experts (CUME): T-shaped uterus. 61
31432589 2019
35
Surgical management of congenital uterine anomalies (including indications and surgical techniques). 61
30910446 2019
36
Characteristics of midluteal phase uterine artery hemodynamics in patients with recurrent pregnancy loss. 61
30977230 2019
37
Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study. 61
31348233 2019
38
Machine learning for classification of uterine activity outside pregnancy. 61
31946329 2019
39
Uterine endometrial cytology, biopsy, bacteriology, and serum C-reactive protein in clinically healthy diestrus bitches. 61
30974392 2019
40
[NON-RESECTOSCOPIC ABLATION OF ENDOMETRY IN BENIGN UTERINE DISEASES (REVIEW)]. 61
31418727 2019
41
Management of Acute Obstructive Uterovaginal Anomalies: ACOG Committee Opinion, Number 779. 61
31135762 2019
42
Asymptomatic microperforated transverse vaginal septum presenting with primary infertility: a rare form of mullerian anomaly. 61
31360591 2019
43
Management of Acute Obstructive Uterovaginal Anomalies: ACOG Committee Opinion Summary, Number 779. 61
31135759 2019
44
Sonographically Guided Office Endometrial Sampling: Indications and Results. 61
30251435 2019
45
Urinary incontinence following subtotal and total hysterectomy: a systematic review. 61
31066798 2019
46
B cell activation factor (BAFF) induces inflammation in the human fallopian tube leading to tubal pregnancy. 61
31088412 2019
47
Expression of Antioxidant Enzymes in Patients with Uterine Polyp, Myoma, Hyperplasia, and Adenocarcinoma. 61
30978928 2019
48
Preterm birth: seven-year retrospective study in a single centre population. 61
30971310 2019
49
A case of 20-week abortion in a rare communicating rudimentary horn of a misinterpreted unicornuate uterus, incorrectly diagnosed as bicornuate: A serious hazard! 61
30846246 2019
50
Double Cervix with Normal Uterus and Vagina - An Unclassified Müllerian Anomaly. 61
30644250 2019

Variations for Uterine Anomalies

Expression for Uterine Anomalies

Search GEO for disease gene expression data for Uterine Anomalies.

Pathways for Uterine Anomalies

Pathways related to Uterine Anomalies according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR34C MIR34A MIR30A MIR214 MIR21
2 11.26 MIR34C MIR30A MIR17
3 10.37 MIR199A1 MIR145
4 9.56 ESR1 CYP19A1

GO Terms for Uterine Anomalies

Biological processes related to Uterine Anomalies according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10 MIR9-1 MIR218-1 MIR214 MIR21 MIR15A
2 negative regulation of gene expression GO:0010629 9.92 MIR214 MIR21 MIR17 ESR1
3 positive regulation of protein kinase B signaling GO:0051897 9.88 MIR21 MIR199A1 MIR143 ESR1
4 positive regulation of angiogenesis GO:0045766 9.84 MIR30A MIR21 MIR199A1 MIR143
5 negative regulation of cell migration GO:0030336 9.8 MIR9-1 MIR34A MIR218-1 MIR214 MIR21
6 negative regulation of angiogenesis GO:0016525 9.8 MIR34A MIR214 MIR21 MIR15A MIR145 MIR143
7 negative regulation of protein kinase B signaling GO:0051898 9.77 MIR34C MIR34A MIR145
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.74 MIR214 MIR21 MIR17
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR30A MIR200A MIR143
10 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.69 MIR34A MIR214 MIR15A
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.67 MIR21 MIR199A1 MIR145
12 positive regulation of connective tissue replacement GO:1905205 9.67 MIR34C MIR34A MIR214 MIR199A1
13 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.65 MIR34A MIR17
14 negative regulation of cardiac muscle hypertrophy GO:0010614 9.65 MIR21 MIR145
15 negative regulation of sprouting angiogenesis GO:1903671 9.65 MIR34C MIR34A MIR17
16 regulation of smooth muscle contraction GO:0006940 9.64 MIR145 MIR143
17 uterus development GO:0060065 9.64 ESR1 CYP19A1
18 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.63 MIR199A1 MIR17
19 androgen metabolic process GO:0008209 9.63 ESR1 CYP19A1
20 positive regulation of metalloendopeptidase activity GO:1904685 9.62 MIR21 MIR17
21 angiotensin-activated signaling pathway GO:0038166 9.61 MIR145 MIR143
22 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR21 MIR17
23 negative regulation of lamellipodium assembly GO:0010593 9.58 MIR214 MIR196A1
24 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR34C MIR214 MIR199A1 MIR17
25 aorta smooth muscle tissue morphogenesis GO:0060414 9.55 MIR145 MIR143
26 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.55 MIR34A MIR218-1 MIR214 MIR21 MIR15A
27 regulation of phenotypic switching GO:1900239 9.52 MIR145 MIR143
28 miRNA mediated inhibition of translation GO:0035278 9.5 MIR9-1 MIR30A MIR218-1 MIR21 MIR17 MIR15A
29 gene silencing by miRNA GO:0035195 9.5 MIR9-1 MIR34C MIR34A MIR30A MIR218-1 MIR214
30 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.46 MIR17 MIR143
31 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143

Molecular functions related to Uterine Anomalies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR9-1 MIR34A MIR30A MIR218-1 MIR214 MIR21

Sources for Uterine Anomalies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....